Abstract

Thromboembolic events, principally stroke, represent among the leading causes of morbidity and mortality of subjects with atrial fibrillation, with an incidence about 5 times higher compared to healthy subjects. Chronic kidney disease, frequently associated with atrial fibrillation, determines itself a further increase of thromboembolic events, bleeding and mortality. In addition, the presence of renal failure complicates the pharmacological management of these patients, mainly due to the side effects of antiarrhythmic and anticoagulant drugs with renal excretion, due to their accumulation. Apixaban is a new oral anticoagulant characterized by good bioavailability and renal elimination accounting for only 25%, showing a safety profile and effectiveness in patients with renal impairment, who very often are under-treated or inadequately treated during atrial fibrillation. In this manuscript, we reviewed the data available in the literature regarding the use of apixaban in the management of non-valvular atrial fibrillation in patients with renal failure, in order to clarify an often-debated topic in clinical practice. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Autore Pugliese

• Franchini Carlo , Corbo Filomena Faustina Rina , Ciccone Marco Matteo

Tutti gli autori

• FRANCHINI C.;CORBO F.F.R.;CORTESE F.;RICCI G.;CICCONE M.M.;GESUALDO M.;SCICCHITANO P.;CARBONARA S.

Titolo volume/Rivista

Non Disponibile

Anno di pubblicazione

2017

ISSN

0929-8673

ISBN

Non Disponibile

Numero di citazioni Wos

Nessuna citazione

Ultimo Aggiornamento Citazioni

Non Disponibile

Numero di citazioni Scopus

Non Disponibile

Ultimo Aggiornamento Citazioni

Non Disponibile

Settori ERC

Non Disponibile

Codici ASJC

Non Disponibile